Skin microbes linked to vitiligo and immunotherapy reactions in melanoma patients
NCT ID NCT04734704
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether the community of bacteria living on the skin (the skin microbiome) plays a role in vitiligo—a condition that causes white patches—and in side effects from anti-PD-1 immunotherapy for advanced melanoma. Researchers will collect skin swabs from people with vitiligo, melanoma patients who developed vitiligo during treatment, and those who did not. By analyzing the genetic material of skin microbes, they hope to uncover connections that could lead to better understanding of these conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal how skin microbes influence autoimmune conditions and treatment side effects, potentially guiding future therapies.
- What could go wrong
- This is an observational study with a small sample size (57 people). It aims to understand, not treat, so direct patient benefits are not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Dermatologie - Hôpital Saint-André
Bordeaux, Bordeaux, 33075, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can Real-World data unlock better skin disease care?
- Could a personal coach at home boost energy for cancer patients?
- New melanoma drug aims to match Keytruda's success
- Could a cheaper copy of keytruda work just as well against cancer?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?